Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia (NASDAQ: LQDA) announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will update the company's business at the 2024 Jefferies Global Healthcare Conference. The presentation will take place on June 5, 2024, at 9:00 a.m. ET in New York City. A webcast of the event will be available on Liquidia's website, with an archived version accessible for at least 30 days post-event.
Positive
- Presentation by top executive Michael Kaseta at a significant healthcare conference can boost investor confidence.
- Webcast availability increases transparency and accessibility for investors and stakeholders.
Negative
- No new financial data or clinical trial information provided in the press release.
- Potential dilution of investor interest if no significant new information is shared during the presentation.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was +1.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company's business during a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday June 5, 2024, beginning at 9:00 a.m. ET, in New York City, NY.
Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a next-generation nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.